This site is intended for healthcare professionals

Breaks in TKI therapy may not affect the outcomes of renal cell carcinoma

Time : 8th of March 2023 11:09:55 AM Oncology,Nephrology

Researchers did not find a clinically meaningful reduction in survival outcomes of patients with advanced renal cell carcinoma who discontinued the planned treatment of tyrosine kinase inhibitor compared to those who continued the planned treatment. However, the study could not determine the non-inferiority of treatment cessation to treatment continuation.
  Cancer Network

Study suggests not giving hydrochlorothiazide to prevent kidney stones

Time : 6th of March 2023 10:51:12 AM Physician/Medicine,Nephrology

The incidence of kidney stone recurrence was not substantially different among people on various doses of HCT or placebo, as per a study. On the other hand, new-onset diabetes mellitus, gout, skin allergy, hypokalemia, and higher plasma creatinine levels over 150% were more common in people on HCT than in those on placebo, suggesting the dangers of using HCT.
  Twitter @NEJM

Renal denervation lowers systolic blood pressure

Time : 3rd of March 2023 11:17:14 AM Radiology,Physician/Medicine,Nephrology,Cardiology

Patients with hypertension who were not on antihypertensives and underwent renal denervation reduced daytime ambulatory systolic BP by 7.9 mm Hg compared to 1.8 mm Hg in those who underwent a sham procedure, as per a study. The ultrasound renal denervation effects were consistent throughout a 24-hr circadian cycle. Moreover, 6 out of 7 secondary outcomes also improved with it.
  Health Day

Simultaneous heart-kidney transplant is linked to better survival

Time : 21st of February 2023 04:28:34 PM Physician/Medicine,Nephrology,Cardiology

Compared to heart transplantation alone, heart-kidney transplantation was tied to better survival in patients with moderate kidney disease regardless of dialysis status, as per a study. The 5-year mortality in heart-transplant recipients was 38.6% compared to 26.7% in heart-kidney transplant recipients. The survival benefit of heart-kidney transplant lasted till eGFR of 40.

FDA grants accelerated approval for a drug to treat IgAN

Time : 20th of February 2023 12:31:06 PM Pharma News,Nephrology

Filspari (sparsentan) is approved for treating proteinuria in adults with primary IgA nephropathy at risk of progression. It is the only non-immunosuppressive and once-daily oral drug approved for this condition. It targets angiotensin II and endothelin-1 and can ultimately become a new standard of care. It comes with a boxed warning of teratogenicity and hepatotoxicity.
  Travere Therapeutics

Gadolinium in MRI contrast agents can infiltrate kidneys

Time : 20th of February 2023 11:53:13 AM Radiology,Physician/Medicine,Nephrology

The contrast agents given as infusion to enhance MRI scans contain a rare earth element called gadolinium. Researchers found it could leech from the contrast agent and enter kidney tissues to start nephrogenic systemic fibrosis, which can be fatal. But how the metal detaches from the contrast agent and why only some people develop kidney events is not known.
  University of New Mexico

Can you cut back on sodium bicarbonate pills in kidney transplant recipients?

Time : 17th of February 2023 11:09:30 AM Nephrology,General Surgery

Sodium bicarbonate used to correct metabolic acidosis and prevent declining graft function in kidney transplant recipients was found not to affect the decline in eGFR, a surrogate marker for graft function, as per a study. The findings suggest sodium bicarbonate should not be advised to preserve eGFR in transplant recipients with kidney disease and metabolic acidosis.
  Twitter @TheLancet

FDA approves an oral drug for anemia in kidney patients on dialysis

Time : 2nd of February 2023 11:59:41 AM Pharma News,Nephrology

Jesduvroq tablets (daprodustat) became the first oral medicine approved for treating anemia in adults on dialysis for 4 or more months due to chronic kidney disease. The drug increased and maintained hemoglobin levels in patients in a trial by increasing erythropoietin levels. It comes with boxed warnings of blood clotting events, heart attack, death, stroke.

New KDIGO guidelines for managing diabetes and chronic kidney disease

Time : 10th of January 2023 12:18:21 PM Nephrology,Endocrinology & Diabetes

The updated guidelines highlight the evidence on the safety and role of SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and GLP-1 receptor agonists for managing patients with type 2 diabetes and CKD. The guidelines stressed equitable access to these drugs by prescribing them, lowering their prices and making them available as generic formulations.

Gambia's committee names Maiden as responsible for kidney injury deaths in kids

Time : 23rd of December 2022 02:02:16 PM Pharma News,Paediatrics,Nephrology

Gambia's parliamentary committee said that India-based drug manufacturer Maiden Pharmaceuticals was responsible for the deaths of 70 kids due to AKI. The committee also called on for legal action. Another committee also reached the same conclusion after an investigation. WHO's lab analysis confirmed the presence of unacceptable levels of ethylene glycol and diethylene glycol.
  US News